{'fraction_non_alphanumeric': 0.017107309486780714, 'fraction_numerical': 0.006220839813374806, 'mean_word_length': 6.076923076923077, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clozapine‐induced hepatitis confirmed by rechallenge

Clozapine is an atypical antipsychotic that holds a unique role in the management of treatment‐resistant schizophrenia. Well known side‐effects include agranulocytosis and myocarditis but associated hepatic disorders are less familiar and listed under ‘rare or very rare’ by the British National Formulary.1 However, a transient elevation of transaminases has been estimated to affect up to 50% of patients treated with clozapine.2 This article describes a patient with minimally elevated LFTs who subsequently developed symptomatic hepatitis following the initiation of clozapine therapy.